Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions

By Givant-Horwitz V.   Davidson B.   Lazarovici P.   Schaefer E.   Nesland J.M.   Trope C.G.   Reich R.  

Gynecologic Oncology, Vol. 91, Iss. 1, 2003-10 ,pp. : 160-172

Elsevier

Access to resources Recommend Favorite

Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions

By Miller Brigitte  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 27-28

Informa Healthcare

Access to resources Recommend Favorite

EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma

By Davidson Ben   Goldberg Iris   Berner Aasmund   Kristensen Gunnar   Reich Reuven  

Clinical and Experimental Metastasis, Vol. 20, Iss. 2, 2003-03 ,pp. : 161-169

Springer Publishing Company

Access to resources Recommend Favorite

FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome

By              

International Journal of Oncology, Vol. 42, Iss. 3, 2013-01 ,pp. : 912-920

Spandidos Publications

Access to resources Recommend Favorite

Extended Surgical Staging for Uterine Papillary Serous Carcinoma: Survival Outcome of Locoregional (Stage I-III) Disease

By Bristow R.E.   Asrari F.   Trimble E.L.   Montz F.J.  

Gynecologic Oncology, Vol. 81, Iss. 2, 2001-05 ,pp. : 279-286

Elsevier

Access to resources Recommend Favorite